Yahoo Finance25d
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
In the overall study population, TX45 achieved a 17.9% reduction in pulmonary capillary wedge pressure (“PCWP”), an endpoint known to correlate with exercise capacity, morbidity and mortality ...
Hosted on MSN24d
Tectonic Therapeutic stock soars on positive trial data
Tectonic reported that TX45 achieved a 17.9% reduction in Pulmonary Capillary Wedge Pressure (PCWP) across the study population. Moreover, in a subset of patients with more severe disease ...
TCTMD13d
Assessing Determinants of Maximal Exercise Tolerance: What Are the Relative Contributions of PCWP, Ventilatory Anaerobic Threshold and Lactate
Time to Escalation: From the Golden Day to the Golden Six Hours Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the ...
TX45临床试验显示积极结果：心衰与肺动脉高压患者的潜在新疗法
Tectonic Therapeutic公司近日公布了其候选药物TX45在1b期临床试验中取得的积极中期数据，尤其是在患有2型肺动脉高压合并射血分数保留型心力衰竭（PH-HFpEF）的患者中。此次临床数据表明，单次静脉输注TX45显著改善了这些患者的左心室功能和肺部血流动力学。
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”), supporting ...